Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Precision BioSciences, retaining the price target of $60.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio’s rating is based on the promising initial Phase 1 data from Precision BioSciences’ ELIMINATE-B trial, which evaluates the gene editing therapy PBGENE-HBV. The data demonstrated significant reductions in HBsAg levels in patients at the lowest dose, with one patient showing a sustained reduction over seven months. Importantly, no serious adverse events or dose-limiting toxicities were observed, indicating a favorable safety profile.
Trucchio sees the ongoing dose escalation and the potential for increased dosing frequency as critical steps in maximizing the therapy’s efficacy. The upcoming liver biopsy data is expected to provide further confirmation of the therapy’s intrahepatic editing capabilities. With the therapy targeting the root cause of HBV persistence, and a strong financial position extending into the second half of 2027, Trucchio views PBGENE-HBV as a groundbreaking opportunity in the field of viral hepatitis, justifying the Buy rating and $60 price target.
In another report released today, JonesTrading also maintained a Buy rating on the stock with a $30.00 price target.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DTIL in relation to earlier this year.